|Home | About | Journals | Submit | Contact Us | Français|
Chronic infection with hepatitis B virus (HBV) greatly increases the risk for liver cirrhosis and hepatocellular carcinoma (HCC). HBV isolates worldwide can be divided into 10 genotypes. Moreover, the immune clearance phase selects for mutations in different parts of the viral genome. The outcome of HBV infection is shaped by the complex interplay of the mode of transmission, host genetic factors, viral genotype and adaptive mutations, as well as environmental factors. Core promoter mutations and mutations abolishing HBeAg expression have been implicated in acute liver failure, while genotypes B, C, subgenotype A1, core promoter mutations, preS deletions, C-terminal truncation of envelope proteins, and spliced pregenomic RNA are associated with HCC development. Our efforts to treat and prevent HBV infection are hampered by the emergence of drug resistant mutants and vaccine escape mutants. This paper provides an overview of the HBV life cycle, followed by review of HBV genotypes and mutants in terms of their biological properties and clinical significance.
About 240 million people worldwide are chronically infected with hepatitis B virus (HBV), which put them at great risk to develop liver cirrhosis and hepatocellular carcinoma (HCC) . Both viral and host factors contribute to the outcome of HBV infection. In this review we will discuss the current state of knowledge regarding HBV genetic variants, including their role in establishment and maintenance of chronic infection, disease progression, pathogenesis, and treatment response. To better understand these topics, a brief overview of the HBV life cycle is essential.
HBV is the prototype of a group of hepatotropic DNA viruses infecting birds (ducks, geese, herons) and mammals (woodchucks, ground squirrels, bats) . The 42-nm infectious virion has an internal capsid (core particle) of 27nm to shield a partially double stranded DNA genome of unusual structure. Upon infection of hepatocytes, the relaxed circular (RC) DNA is released and converted to covalently closed circular (ccc) DNA form  (Fig. 1). The cccDNA, which forms a minichromosome with high stability (see companion paper by Lucifora and Protzer), is the template for transcription of viral mRNAs utilizing host DNA-dependent RNA polymerase. As this unleashes viral protein expression and genome replication, the cccDNA is the intracellular seed for initiation of the viral life cycle.
The 3.2-kb HBV genome is the smallest among DNA viruses but also one of the most compact. First, every nucleotide in the cccDNA has coding capacity. Second, the polymerase (P) gene overlaps with the 3’ end of core gene, the entire envelope gene, and the 5’ end of X gene (Fig. 2). Third, related but functionally distinct core and envelope proteins are generated by alternative translation initiation from in-frame AUG codons. Alternative use of the preS1, preS2, and S AUGs in the envelope gene generates large (preS1+preS2+S), middle (preS2+S), and small (S) envelope proteins. Similarly, expression of precore/core and core proteins depends on translation initiation from the precore AUG and core AUG, respectively. Fourth, multiple transcripts are employed to express the seven viral proteins, and the promoters and enhancers needed to generate such transcripts overlap with the coding sequences. Compactness of the HBV genome causes pleiotropic effect of many naturally occurring mutations, thus complicating our efforts to dissect molecular mechanisms of HBV pathogenesis.
Four promoters: core, SPI, SPII, and X, drive transcriptional initiation at different positions in the HBV genome to generate the 3.5-, 2.4-, 2.1-, and 0.7-kb polyadenylated RNAs, respectively. The four classes of RNAs are co-terminal at the 3’ end due to a single polyadenylation signal in the viral genome (Fig. 2). Transcription of these RNAs is further augmented by two enhancer elements and also by HBx (X gene product), a weak transcriptional transactivator with pleiotropic effect . HBx is required for initiation of HBV infection and has been implicated in hepatocarcinogenesis (see companion paper by Levrero and Zucman-Rossi).
The four classes of unspliced HBV RNAs are exported to cytoplasm for protein translation and DNA replication (Fig. 1). The 2.4- and 0.7-kb mRNAs produce L and HBx proteins, respectively, while the heterogeneous 5’ end of the 2.1-kb mRNA enables it to produce both M and S proteins, with the latter being predominant. Similarly, the longer and shorter versions of the 3.5-kb RNA, called precore RNA and pregenomic (pg) RNA, are respectively responsible for the expression of precore/core and core proteins. Cleavage of the N-terminal signal peptide as well as C-terminal arginine-rich sequence converts the precore/core protein to hepatitis B e antigen (HBeAg), a secreted protein dispensable for replication per se but critical for the establishment of chronic infection. The 5’ end of the P gene overlaps with the 3’ end of the core gene, and P protein is translated from pgRNA through ribosomal leaky scanning past the core gene AUG. The outcome is low P/core protein ratio conducive to DNA replication, which is catalyzed by probably just one copy of P protein packaged inside core particles assembled from 180 or 240 copies of core protein.
pgRNA is the only HBV transcript required for genome replication. Besides serving as bicistronic mRNA for core and P proteins, it is also the RNA molecule to be packaged inside core particle for conversion to progeny DNA . Selective packaging of pgRNA but not shorter transcripts is attributed to an RNA secondary structure (ε signal) at its 5’ end. The co-packaged P protein, which contains four structural domains in the order of terminal protein-spacer -reverse transcriptase - RNase H (Fig. 3), catalyzes minus strand DNA synthesis by reverse transcription from the pgRNA template. A tyrosine residue on its terminal protein domain serves as the acceptor site for the first nucleotide of minus strand DNA. The error-prone nature of reverse transcription causes a high mutation rate, estimated at 10-3-6 substitutions per replication cycle according to various investigators [6-13]. That provides a large repertoire of genetic variants for selective outgrowth at different stages of infection. Next, the RNase H domain cleaves pgRNA, with its 5’ most remnant serving as the primer for plus strand DNA synthesis. The core particle is subsequently enveloped by the three envelope proteins and virions are budded through the multivesicular bodies . Surprisingly, majority of virions contain no DNA at all, apparently because core particle assembly does not require pgRNA packaging . The functional significance of such a defective but perhaps interfering form of virions in the natural course of HBV infection, if any, remains to be established.
Alternative to their envelopment and release as infectious virions, core particles with mature viral genome can traffic back to the nucleus where the RC DNA is converted to cccDNA (Fig. 1). This intracellular route of cccDNA amplification ensures enough copies of cccDNA per cell to sustain persistent infection. Besides RC DNA, double stranded linear DNA can also be generated from pgRNA template due to the lack of template switch during DNA synthesis. Inside nucleus such linear DNA is the preferred template for integrating into host chromosomal DNA. Integration does not play any role in HBV life cycle, but may contribute to HCC formation depending on the integration site.
Besides virions, the majority of the S protein is secreted as the 22-nm subviral particles lacking internal capsids [14, 16]. Subviral particles outnumber virions by 1,000 fold or greater and are detected serologically as hepatitis B surface antigen (HBsAg). It was the serendipitous detection of HBsAg from Australia aborigines 50 years ago that led to the discovery of the etiological agent for hepatitis B .
Liver cirrhosis and HCC do not stem from acute HBV infection. Rather, they are the consequences of repeated cycles of hepatocyte destruction and regeneration during the immune clearance phase of chronic HBV infection. Consequently, risk for such chronic liver diseases is elevated by host and viral factors that 1) predispose to the establishment of chronic infection, and 2) prolong the immune clearance phase or increase the total cycles of hepatocyte turnover during this phase. In this regard HBV isolates worldwide were initially classified into eight genotypes (A to H) and further divided into subgenotypes based on nucleotide sequence divergence of the entire genome by 8% and 4%, respectively [18-24]. While most genotypes have a genome size of 3215 nucleotides (nt), genotypes A, D, E, and G have a genome of 3221, 3182, 3212, and 3248 nt, respectively due to in-frame insertion or deletion (Table 1). Genotypes A - D are the best characterized, with genotype A most frequent in North America and Africa, genotypes B and C the dominant viruses throughout East Asia, and genotype D most common in Southern Europe and India (Table 1). Genotype E is largely restricted to Sub Saharan Africa, while genotypes F and H co-circulate in indigenous peoples of South America. Genotype G is unusual in its high infection rate in men having sex with men, co-infection with another HBV genotype and HIV, and association with increased risk for liver fibrosis [25-28]. In this regard the unique 36-nucleotide insertion in its core gene causes genotype G to overproduce core protein [29-30]. Genotypes E, G, and H have no subgenotypes, suggesting their recent origin. In contrast, genotype C has 16 subgenotypes and is probably the oldest HBV genotype . Among the HBV subgenotypes, A1 is largely restricted to Africa and India [31-34], B1 to Japan, and C4 to indigenous Australians [35-36]. In Korea only the C2 subgenotype is found [37-38]. Nevertheless, geographic distribution of HBV genotypes is being increasingly altered through travel and migration, as demonstrated by the emergence of European, Asian and African genotypes in countries of low HBV endemicity such as Australia (Bannister E, personal communication).
The same host can be infected by different HBV genotypes, as best demonstrated by the sensitive next generation sequencing technology if one genotype dominates over the other (which is often the case) [26, 39-42]. The consequences of co-infection include genotype switch when the selection pressure changes [25-26, 43-44], and formation of recombinant virus [45-46]. Thus, the core gene of subgenotypes B2 - B5 originated from genotype C , while the dominant HBV found in Tibet is a recombinant between genotypes C and D . Recombinants have also been identified for genotypes A/D, G/C and D/E, such as between D7 and E in Africa . While most recombination breakpoints occur in the precore/core region , subgenotype C4 identified exclusively in Australian aborigines has a genotype C2 backbone but an S region of genotype J (see below) .
In 2000 three full-length HBV genomes from Vietnam were found to display unusual phylogenetic features. While a 2.2-kb genomic fragment was remotely related to genotype A, the remaining sequence aligned best with genotype C . Further analysis revealed alignment of the preS and S regions with genotypes A and G, respectively, and the remaining sequence with subgenotype C4 . Assigning such recombinant HBV to genotype I was met with resistance, because their divergence from many genotype C isolates was less than 8%. However, with the isolation of similar viruses from Laos and eastern India [52-53], the cutoff for genotypic divergence was reduced to 7.5% and genotype I was recognized . This new genotype is common in Southern China bordering with Vietnam, and has been associated with HCC development . Transfection experiments of a genotype I clone in cell culture and mice suggested its competence in genome replication and expression of HBsAg and HBeAg . Putative genotype J was isolated from an 88-year old Japanese male who probably contracted HBV infection while stationed in Borneo, a South East Asian island. The complete genome of this single isolate (3182 nt) differs from genotypes A-I by at least 9.9%, with the least divergence from a gibbon HBV genome . It is probably a recombinant between gibbon HBV and human HBV genotype C , or represented cross-species transmission to human. The particular genotype J isolate was infectious in mice repopulated with human hepatocytes .
Age of transmission is the most critical host factor for the establishment of chronic infection (defined by HBsAg positivity for more than 6 months). Thus, more than 90% of perinatal transmission from HBeAg-positive mothers ends up with chronic infection, in contrast to less than 5% of transmission during adulthood. Genotypes B and C are transmitted primarily by the perinatal route leading to high prevalence of chronic HBV infection in East Asia. In contrast, genotypes A and D are usually acquired by horizontal transmission in adulthood (subgenotype A2) or adolescence (genotype D). Studies from Japan revealed higher propensity of the exotic subgenotype A2 to cause chronic infection than genotype B or C during sexual transmission [58-59]. In Europe genotype A was associated with chronic infection in contrast to a much greater contribution of genotype D to acute infection .
Even within the same genotype considerable differences in HBV natural history and pathogenesis can be identified, perhaps best exemplified by subgenotypes A1 and A2. A2 (European/North American) is almost always acquired in adulthood and is rarely associated with liver cancer. In stark contrast, A1 (African/Indian) is transmitted in early childhood and associated with rapid progression to liver cancer, without underlying cirrhosis, in young African males [32-33, 61]. In fact adolescents infected with subgenotype A1 are 4.5 times more likely to develop liver cancer than persons infected with other African genotypes [32-34]. Besides viral factors, contribution of confounding environmental and host factors cannot be excluded.
The viral factors facilitating the establishment of chronic infection are HBeAg and excess subviral particles, traits of the wild-type virus. Both antigens have been implicated in the induction of immune tolerance. HBeAg is derived from the precore/core protein by removal of the N-terminal signal peptide of 19 residues followed by furin cleavage of the C-terminal 29 residues . However, genotype A has altered furin cleavage sites to produce additional larger sized forms of HBeAg , although the functional significance remains uncertain. Whereas the core protein activates type I T helper (Th1) cells leading to immune attack, HBeAg triggers Th2 type responses promoting immune tolerance. Importantly, it promotes a switch of the immune response to core protein from Th1 to Th2 [64-66]. HBeAg can also cross the placenta to establish immune tolerance in the developing fetus, and suppress a range of innate immune signaling pathways [67-71]. Although acute infection is observed in newborns of women infected with HBeAg-negative HBV, lack of HBeAg expression prevents the establishment of persistent infection. Similarly, genotype G is unable to express HBeAg due to double precore nonsense mutation, which may partly explain why chronic genotype G infection does not occur alone but rather in association with another HBV genotype as the source of HBeAg [25-26, 72].
Immune tolerance induced by HBeAg and HBsAg does not last forever, as evidenced by two seroconversion events: loss of HBeAg followed by rise of anti-HBe antibody, and loss of HBsAg followed by rise of anti-HBs. The first seroconversion is usually accompanied by marked drop in viremia titer, while the second seroconversion coincides with clearance of viremia. The humoral and cell-mediated immunities provide the driving force for replacement of wild-type HBV with various mutants, and also greatly increase sequence heterogeneity to generate viral quasispecies [73-74]. The mutations selected help to reduce or abolish production of HBeAg or subviral particles (as they no longer promote viral persistence), to alter antigenic epitopes of the core or envelope proteins for immune escape, or to augment replication capacity to compensate for virus destruction.
In the Mediterranean region, patients who seroconvert from HBeAg to anti-HBe may continue to suffer from severe liver diseases, and the search for the “Mediterranean variant” led to the identification of mutations in the precore region preventing HBeAg expression [75-77]. The most common is G1896A converting TGG to TAG, a stop codon. Subsequent studies revealed presence of such mutants elsewhere. Instead of patients being infected with the G1896A mutant, the G1896A mutation arises de novo around the time of HBeAg seroconversion. Interestingly, genotypes A and D co-circulate in the Mediterranean region, but genotype A rarely develops the G1896A mutation. In this regard the precore region overlaps with the ε signal essential for pgRNA packaging, and the G-to-A substitution would improve a U1858 – G1896 base pair in genotype D but disrupt a preexisting C1858 – G1896 base pair in genotype A . Genotype H, subgenotypes C1, F2, and F3 also have C1858 and are similarly hampered in developping the G1896A mutation [79-80]. As expected the G1896A mutation correlates with lower HBeAg levels in vivo , which are associated with improved response to interferon treatment . On the other hand, presence of G1896A mutation at as low as 1% of the quasispecies pool has been shown to negatively impact HBsAg loss to tenofovir treatment in genotype A and D patients, for unknown reasons .
The core promoter, which drives transcription of precore RNA and pgRNA, can be divided into basic core promoter (BCP) and core upstream regulatory sequence. The A1762T/G1764A double mutation is the most common BCP mutation, which can be accompanied by additional mutations nearby . The BCP mutations reduce, but do not abolish, HBeAg expression [85-86]. They provide a mechanism whereby HBV genotypes unable to develop the G1896A mutation can suppress HBeAg expression. Indeed, such mutations are more prevalent in genotype A than genotype D [87-88] and in subgenotype C1 than C2 [89-91]. Experiments performed in cell culture confirmed their down regulation of precore RNA to reduce HBeAg expression, but also revealed up regulation of pgRNA to enhance genome replication [92-93]. Whereas the A1762T/G1764A double mutation reduces HBeAg expression less than 30% while increasing genome replication 2 fold, up to 80% reduction in HBeAg expression and 20 fold increase in genome replication can be achieved when additional mutations such as T1753C, C1766T, and T1768A are present [92, 94-95]. Therefore, BCP and precore mutations have distinct functions, and they can coexist in the same genome.
Acute liver failure stems from rapid and massive virus infection of the liver accompanied by equally vigorous immune attack, and HBV isolates implicated in acute liver failure often harbor BCP mutations to augment genome replication in addition to the G1896A precore mutation to abolish HBeAg expression [96-101]. Increased pgRNA transcription will inevitably increase core protein expression to attract greater immune attack. The replication impact of BCP mutations could also explain their higher prevalence in genotype C than genotype B [90, 102-103], as genotype C isolates with wild-type BCP sequence in general displayed lower replication capacity than genotype B isolates, at least in cell culture . Such a low replication capacity may extend the immune tolerance phase, while replacement of the wild-type virus by BCP mutant at the immune clearance phase could prolong survival. These features probably could explain why genotype C patients seroconvert from HBeAg to anti-HBe about a decade later than genotype B patients [105-108], and why such patients have increased lifelong risk to develop liver cirrhosis and HCC [90, 109-111]. In fact BCP mutations were strongly associated with cirrhosis and HCC development irrespective of the viral genotype [111-116]. Recent studies using ultradeep sequencing have shown that patients harboring a high proportion of BCP mutants (≥ 45%) one year after HBeAg seroconversion have a greater likelihood of progressing to cirrhosis than those with a lower mutant percentage(<10%) .
BCP overlaps with the X gene, with the T1753C, A1762T, G1764A, and T1768A mutations causing I127T, K130M, V131I, and F132Y mutations in HBx protein, respectively. Some of these mutations have been found to abolish the growth inhibitory effect of wild-type HBx protein, partly through down regulation of p21, a tumor suppressor [117-118]. These findings reveal an alternative mechanism whereby BCP mutations promote HCC formation.
Subviral particles are not essential for HBV life cycle, and marked reduction in the expression of envelope proteins did not impair virion secretion if a proper L/S protein ratio was maintained . Furthermore, a genome defective in envelope protein expression can be rescued by envelope proteins produced by another genome in the same cell (transcomplementation). Thus, envelope protein expression can be down regulated. Since anti-preS and anti-S antibodies are neutralizing, mutating the corresponding B cell epitopes could escape neutralization to prolong survival.
Large in-frame deletions have been detected in the preS regions of the envelope gene, often clustered at the 3’ end of preS1 and 5’ end of preS2 [120-122]. These deletions are mostly found in genotypes A1, B and C, probably related to their prolonged replicative phase (longest for genotype C) in association with perinatal transmission. Although preS deletions are detectable in some cirrhotic samples, their highest prevalence was found in HCC tissues [122-125]. Presence of such deletions in childhood HCC reinforces its active role in hepatocarcinogenesis [126-127]. The deletions remove C-terminal preS1 domain or N-terminal preS2 domain in the L protein, and in the latter case will prevent M protein expression. Although large deletions are introduced to P protein as well, this corresponds to the spacer region not critical for its function. Nevertheless, the junction between preS1 and preS2 domain is required for virion formation , therefore the deletion mutants may be impaired in transmission if unaccompanied by wild-type virus. The preS1 region also corresponds to the SPII promoter for transcription of the 2.1-kb RNA, hence such deletions could reduce S protein expression at the transcriptional level. So far limited experiments have been performed to validate the functional consequences of preS deletions. On the other hand, significant progress has been made in elucidating their mechanisms of hepatocarcinogenesis. Independent studies found that preS deletions are associated with ground glass hepatocytes . In transfection experiments, these deletions caused retention of envelope proteins, triggered ER stress, oxidative stress and DNA damage, and led to cell cycle progression and transformation .
The 3.5-kb HBV RNA can be spliced , although splicing is not essential for HBV DNA replication in vitro. Over a dozen splicing-derived variants have been recognized , and the most common are the 2.2-kb singly or doubly spliced variants. The singly spliced 2.2-kb variant has a 1.2-kb deletion between the 3’ core gene and middle of S region, which prevent the expression of full-length P protein. Instead, the N-terminal 46 residues of the P protein are fused to 47 residues encoded by a different reading frame to generate hepatitis B spliced protein (HBSP) . If provided with intact P protein, this splicing variant can be packaged and replicated. In fact, virions harboring such a shortened HBV genome can circulate in blood of chronic HBV carriers, but not in those recovering from acute infection [131, 133]. In fact increased ratio of the splicing variant relative to wild-type virus in the blood correlates with liver fibrosis and HCC [134-135]. Cell culture studies suggested that HBSP promotes hepatoma cell proliferation and migration . Alternatively, pathogenicity of the splicing variant could be attributed to increased expression of core and HBx proteins as well as DNA replication [133, 137], as a consequence of the large deletion which prevents the transcription of 2.4-kb and 2.1-kb RNAs.
The S domain contains 226 residues, with its immunodominant loop (residues 106-163) exposed on the surface of virions and subviral particles. HBV can be classified into four major serological subtypes: adr, adw, ayr, and ayw, with the “a” determinant (residues 124-147) being the major target of anti-S antibodies developed at the late immune clearance phase. Such antibodies neutralize HBV infectivity by blocking virus binding to heparan sulfate proteoglycans, the low-affinity HBV receptor  (see companion paper by Urban and Li). However, single amino acid substitutions such as G145R could markedly reduce the affinity of anti-S antibodies [139-140], and such immune escape mutants could survive the rising anti-HBs antibody better than wild-type virus. Such mutants could contribute to occult HBV infection, which is defined by presence of HBV DNA but no detectable HBsAg .
The immune escape mutants selected at the late immune clearance phase could delay but not prevent virus elimination, most likely due to additional neutralization by anti-preS1 and anti-preS2 antibodies as well as limited replicative space available. On the other hand, current HBV vaccine consists of yeast-derived recombinant S protein alone . At a time when hepatitis B immune globulin (HBIG) pooled from vaccine recipients was used as the only means to prevent HBV re-infection of the grafted liver, such immune escape mutants were the source of breakthrough infection [143-147]. Currently, children born to HBV infected mothers are given HBIG in addition to HBV vaccine. Unfortunately about 5-10% of such infection cannot be prevented, which could be attributed to intrauterine infection, high maternal viral load, or selection of immune escape mutants [148-149]. Experiments in cell culture suggested that G145R and other immune escape mutants such as T118K, K141E, D144G, C147R, and C149R were severely impaired in virion secretion, which nevertheless could be rescued to various extents by a new N-linked glycosylation site at residue 131 [150-152]. Although T131N/M133T double mutation is needed to create such a glycosylation site for non-A genotypes, coexistence of an escape mutation with the double mutation is not uncommon [144, 153]. Thus, M133T (or N131N/M133T) behaves as a compensatory mutation for G145R. Infection experiments using hepatitis delta virus (HDV), which employs HBV envelope proteins for entry into hepatocytes, suggested that the G145R mutant had sustained infectivity . Therefore, potent immune escape, efficient rescue of virion secretion by compensatory mutation(s), and sustained infectivity could explain why G145R is the most common immune escape mutant.
Current antiviral strategies against chronic HBV infection remain suboptimal [155-156]. To date five nucleos(t)ide analogues (NAs) have been approved for the treatment of HBV infection, namely lamivudine (LMV), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (LdT), and tenofovir (TDF). They act as competitive inhibitors of the reverse transcription step of HBV DNA synthesis (Fig. 1), because their incorporation into the elongating DNA strand leads to chain termination. Potent inhibitors such as ETV and TDF also target the priming step of reverse transcription and can lower viremia to undetectable level . However, NAs do not affect HBeAg or HBsAg expression and are inefficient at promoting HBeAg or HBsAg seroconversion. Consequently they have to be used for prolonged period of time, which may lead to the development of drug resistance. For example, LMV resistant mutations develop in 23% of patients following 12 months of therapy, rising to 80% by five years of treatment . The drug resistant mutations are located in the RT domain of the P protein (Fig. 3). For LMV, rtM204V/I confers drug resistance but also reduces replication capacity, which can be rescued by compensatory mutations such as rtL180M and/or rtV173L [158-159]. ADV resistance is conferred by rtA181T/V or rtN236T mutation. Resistance to ETV requires multiple mutations in addition to those conferring LMV resistance, meaning a higher genetic barrier. However, in the setting of prior resistance to LMV, high rates of resistance to ETV and ADV can occur because of cross-resistance. Although mutations conferring resistance to TDF seem uncommon even following 5 years of treatment [160-161], some mutations may reduce viral sensitivity to TDF therapy .
Due to the overlap between the P and envelope genes, drug resistant mutations in the P gene can cause amino acid substitutions in or near the “a” determinant of envelope proteins, such as F158Y, F161L, E164D, I195M, W196S. Such mutations reduced binding of anti-S antibodies suggesting immune escape [163-164]. The rtA181T mutation can convert codon 172 in the S region into a stop codon, thus truncating the envelope proteins by 55 residues. This mutant was deficient in both virion and HBsAg secretion; it had dominant-negative effect on virion secretion from the wild-type virus . The deletion mutant was associated with an increased HCC risk , possibly due to intracellular retention of the envelope proteins leading to ER stress.
Direct maternal transmission, as best exemplified by genotype C, is the most efficient mechanism whereby HBV has sustained in the human population. Induction of chronic infection is most efficient by the noncytopathic wild-type virus, and requires high doses of HBeAg and HBsAg. On the other hand, mutants replace wild-type virus during immune clearance phase because of their immune escape or higher replication. Consistent with earlier HBeAg than HBsAg seroconversion, core promoter mutations arise much earlier than preS deletions and S domain escape mutations. These mutants contribute to liver diseases including HCC through increased expression of highly immunogenic core protein (core promoter mutants), or envelope protein retention and ER stress (internal deletion of L protein or C-terminal truncation of S protein).
The clinical consequences of HBV mutants can differ between acute and chronic infection. Thus, combination of G1896A and core promoter mutations is associated with acute liver failure, whereas core promoter mutations rather than G1896A mutation is consistently associated with HCC development during chronic infection. Emergence of immune escape mutants in the setting of chronic infection will not prevent eventual HBV clearance, but transmission of such mutants to vaccine recipients may lead to breakthrough infection.
HCC formation is promoted by prolonged HBV infection, high viral load, genotypes B and C, core promoter mutations, preS deletions, truncated S protein, and DNA integration. Although genotype F in general has not been associated with HCC, in Alaska natives genotype F (subgenotype F1) is associated with much higher HCC risk than genotypes A-D [167-168]. In fact the median age of HCC diagnosis was 60 years for genotypes A, C, D combined but only 22.5 years for genotype F. Whether certain biological features unique to these particular subgenotype F1 isolates or compounding host/environmental factors are involved warrants further investigation.
We would like to thank Dr. Yongxiang Wang and Xiaohui Bi for their help in preparation of this manuscript. PR is supported by a Melbourne Health DW Keir Medical Research Fellowship (RF-003-2015). ST has been support by NIH grants AI103648, AI113394 and AI116639.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.